LUX Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
LUX is a transcription factor essential for the generation of the circadian clock oscillation. It is necessary for activating the expression of CCA1 and LHY. LUX is coregulated with TOC1 and appears to be repressed by CCA1 and LHY through direct binding of these proteins to the evening element in the LUX promoter. LUX directly regulates the expression of PRR9, a key component of the morning transcriptional feedback circuit, by binding specific sites on the PRR9 promoter. It binds to its own promoter, inducing a negative auto-regulatory feedback loop within the core clock. LUX binds to ELF3 and associates with ELF4 in a diurnal complex, which is required for the expression of the growth-promoting transcription factors PIF4 and PIF5, subsequently leading to hypocotyl growth in the early evening.
- Transcriptional regulation of LUX by CBF1 mediates cold input to the circadian clock in Arabidopsis. PMID: 24954045
- The in vitro DNA-binding specificity of LUX, its role in the expression of PRR9, and its feedback properties are reported. PMID: 21236673
- LUX ARRHYTHMO (LUX) encodes a Myb domain protein essential for circadian rhythms. [LUX] PMID: 16006522
- The PCL1 gene is the clock oscillator gene essential to the generation of clock oscillation in the higher plant. [PCL1] PMID: 16164597
Q&A
Basic Research Questions
How do I validate LUX antibody specificity in circadian rhythm studies?
-
Perform chromatin immunoprecipitation (ChIP) with primers targeting LUX-binding site (LBS) motifs in promoters of known targets (e.g., EDS1, JAZ5) .
-
Combine with qRT-PCR to verify downstream gene expression changes (e.g., PR1, ICS1, WRKY33) in lux mutants vs wild-type plants .
-
Use isotype controls matching the host species (e.g., mouse IgG3 for anti-LUX antibodies) to rule out nonspecific binding .
What protocols optimize LUX antibody performance in western blotting?
-
Extract proteins during peak LUX expression (ZT1 circadian phase) to maximize detection .
-
Use blocking solutions with 5% nonfat milk in TBST for plant-derived samples to reduce background noise .
-
Validate with tissue from lux mutants as negative controls .
How do I address cross-reactivity concerns with LUX antibodies?
-
Perform bioinformatic analysis of epitope sequences across species (e.g., compare Arabidopsis LUX to homologs in Brassica or Oryza) .
-
Test antibody binding against recombinant LUX protein and deletion mutants in ELISA .
Advanced Research Questions
How does LUX regulate systemic acquired resistance (SAR) in plant-pathogen interactions?
-
Experimental design:
-
Key finding: lux mutants fail to induce SAR, showing 2.5× higher CFU counts than wild-type plants .
Table 1: LUX-dependent gene regulation under defense activation
| Condition | Differentially Expressed Genes (DEGs) | Enriched Pathways |
|---|---|---|
| Col-0 vs lux-1 (ZT1) | 790 DEGs | PTI signaling, SA biosynthesis |
| acd6-1 vs acd6-1lux-1 (ZT1) | 1,180 DEGs | JA signaling, redox balance |
How to resolve contradictions in LUX’s roles as both transcriptional repressor and activator?
-
Method: Cluster RNA-seq data into expression groups (I-III) and analyze promoter LBS motifs .
-
Validation: Use LUX-GFP lines for time-resolved ChIP-seq to map DNA-binding dynamics .
What methods detect neutralizing antibodies against therapeutic LUX formulations?
-
Competitive binding assay: Label LUX with Alexa Fluor 488 and measure displacement by serum antibodies via flow cytometry .
-
Threshold: Neutralization >50% signal reduction at 1:100 serum dilution indicates clinically relevant ADA .
Methodological Guidance for Data Interpretation
How to analyze time-dependent susceptibility in lux mutant phenotypes?
-
Example: Compare PmaDG3 infection outcomes at LL25 (dawn) vs LL37 (dusk):
-
Statistical note: Apply cosinor analysis to model circadian rhythmicity in pathogen response data .
Best practices for longitudinal studies with repeated LUX antibody administrations
-
Monitor lymphocyte depletion via flow cytometry pre- and post-treatment (baseline vs 1-month) .
-
Pre-screen sera for anti-LUX antibodies using single-chain variable fragment (scFv) luciferase reporters .
-
Risk mitigation: Alternate antibody clones (e.g., Fc Silent™ variants) to reduce immunogenicity .
